医学
乳腺癌
内科学
曲妥珠单抗
肿瘤科
病态的
阶段(地层学)
HER2阴性
胃肠病学
癌症
妇科
转移性乳腺癌
生物
古生物学
作者
Reiki Nishimura,Yoshitaka Fujiki,Tetsuhiko Taira,Toshiko Miyaki,Shuichi Kanemitsu,Daisuke Yotsumoto,Megumi Teraoka,Junko Kawano,Naomi Gondo,Reiko Mitsueda,Shinichi Baba,Yasuyo Ohi,Yoshiaki Rai,Yoshiaki Sagara,Yasuaki Sagara
标识
DOI:10.1016/j.clbc.2024.02.013
摘要
HER2-low breast cancer (BC) is a newly defined subset of HER2-negative BC. However, it is still uncertain whether HER2-low BC can be categorized as a distinct biological/clinical subgroup with any prognostic significance.Invasive BC cases (n = 10,215) with Stage I-III were retrospectively analyzed to determine the HER2 status. The HER2 status was then divided into 3 groups: HER2-0, HER2-low, and HER2-positive.The HER2 status was classified as HER2-0 in 1,227 cases (12.0%), HER2-low in 7,209 cases (70.6%), and HER2-positive in 1779 cases (17.4%). HER2-low cases had more positive nodes and were significantly associated with positive ER/PgR, lower nuclear grade, and lower Ki-67 index. HER2-0 had the lowest OS rate in the primary cases and after recurrence. HER2-0 in the node positive group had the lowest OS and was significantly different from HER2-low in the same group. The pathological complete response (pCR) rate for NAC was lowest in the HER2-low group. The DFS after NAC was significantly better in all the pCR cases, regardless of the HER2 status. However, the DFS was significantly lower in the HER2-low non-pCR cases.HER2-low accounted for 70% of the cases and correlated with favorable biological markers. The HER2-low group had a significantly better OS than the HER2-0 group. However, the response to NAC was low in the HER2-low group, and this group had the poorest prognosis among all the non-pCR cases. These findings indicate that HER2-low may have a different biology and prognosis and therefore should be classified as a new entity.
科研通智能强力驱动
Strongly Powered by AbleSci AI